BioEquity Europe 2026

Europe's biotechs can boost asset appeal by adopting "China speed"—using efficient CDMOs to generate first-in-human data faster, shaping early development to drive partnering and valuation. With faster timelines and lower costs from preclinical to approval, Western leaders should leverage China to de-risk assets quickly. This workshop explores China’s development and manufacturing strategy.